MUNICH – German biotech company AMSilk has raised an additional €25 million in an extended Series C financing round to scale the global production of its bio-fabricated silk proteins.
This latest round comes after it raised €29 million in Series C funds back in 2021 and boosts its recent funding levels to €54 million.
The firm reprograms microorganisms to enable them to make silk proteins into usable forms such as powders, hydrogels, fibres, and coatings for various market segments including textiles, medical use and other consumer goods.
Already have an account? Log In
Recommended
Most Popular
Latest Magazine
Features
Why China’s new wastewater standard is only one part of a broader shift spanning environmental law
As Brussels switches on its product passport registry, fashion’s supply chain data gaps threaten a bumpy rollout
As green claims face closer regulatory scrutiny liability no longer sits solely with the brands
News
Preview of our Textile Standards & Legislation Guide
China’s strengthened rules make officials personally accountable for serious environmental damage
New process to strip reactive dyes from cotton could benefit textile-to-textile recycling
Opinion
European factory closures show costs, geography and demand decide which materials survive
Other publications from MCL News & Media
